Loren Data's FBO Daily™

fbodaily.com
Home Today's FBO Search Archives Numbered Notes CBD Archives Subscribe
FBO DAILY ISSUE OF JUNE 07, 2003 FBO #0555
SOLICITATION NOTICE

H -- ThermoFidelase Sequencing

Notice Date
6/5/2003
 
Notice Type
Solicitation Notice
 
Contracting Office
Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852
 
ZIP Code
20852
 
Solicitation Number
Reference-Number-NCI-30068-NV
 
Response Due
6/12/2003
 
Archive Date
6/27/2003
 
Point of Contact
Deborah Moore, Purchasing Agent, Phone (301) 402-4509, Fax (301) 402-4513, - Caren Rasmussen, Lead Contract Specialist, Phone (301) 402-4509, Fax (301) 402-4513,
 
E-Mail Address
dm170b@nih.gov, cr214i@nih.gov
 
Description
The National Institutes of Health (NIH), National Cancer Institute (NCI), Laboratory of Biosystems and Cancer (LBC) intends to procure BAC DNA sequencing from Fidelity Systems Inc., 7961 Cessna Ave, Gaithersburg, MD20879. A mission of the LBC is the studying of tumor suppressor genes. The Genome Structure and Function Section is a research group within LBC, concentrating on the comparison human and non-human primates genes to clarify a role of interspersed mobile elements, including Alu elements in human evolution. High accuracy of BAC DNA sequencing is required to follow evolution of two human disease genes, BRCA1 and MCPH5, and explain a high mutation rate of these genes in primates. Sequencing must be performed directly from BAC template without prior subcloning or PCR amplification of sub-fragments to avoid cloning artifacts and errors during assemble. Fidelity Systems, Inc. is uniquely qualified to perform this sequencing since they have developed a novel method for a high quality DNA sequence analysis based on use of 2'-modified oligonucleotides from 2'-methoxyoxalamido (MOX) and 2'-succinimido (SUC) precursors, "ThermoFidelase" Covered by U.S. Patents 5,427,928, 5,656,463. Patents pending. Sequencing is performed directly from BAC or YAC template without prior subcloning or PCR amplification of sub-fragments. New advanced method produced DNA sequence with no errors. This procurement is commercial as defined in FAR Part 2, and this acquisition is being made in accordance with the test program using simplified procedures for certain commercial items as authorized in FAR 13.5. This is not a request for competitive quotation. However, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow the NCI researcher to determine if the party can perform this requirement. An original and one copy of the capability statements must be received in the contracting office by 1:00 p.m. EDT, on June 12, 2003. All questions must be in writing and can be faxed to (301) 402-4513 or emailed to dm170b@nih.gov . It is the vendor's responsibility to call (301) 402-4509 to insure questions have been received. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. NAICS 541380.
 
Record
SN00340670-W 20030607/030605213251 (fbodaily.com)
 
Source
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)

FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |
ECGrid: EDI VAN Interconnect ECGridOS: EDI Web Services Interconnect API Government Data Publications CBDDisk Subscribers
 Privacy Policy  © 1994-2016, Loren Data Corp.